AnteoTech Limited (ADO.AX)
AUD 0.02
(0.0%)
AUD 0.02
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 23.59 Thousand AUD | 76.89% |
| 2023 | 1.3 Million AUD | 26.41% |
| 2022 | 1.03 Million AUD | -19.39% |
| 2021 | 1.28 Million AUD | 850.47% |
| 2020 | 134.86 Thousand AUD | 0.0% |
| 2019 | - AUD | 0.0% |
| 2018 | - AUD | -100.0% |
| 2017 | 833.88 Thousand AUD | -88.8% |
| 2016 | 7.44 Million AUD | 0.0% |
| 2015 | - AUD | 0.0% |
| 2014 | - AUD | 0.0% |
| 2013 | - AUD | 0.0% |
| 2012 | - AUD | 0.0% |
| 2011 | - AUD | 0.0% |
| 2010 | - AUD | 0.0% |
| 2009 | - AUD | 0.0% |
| 2008 | - AUD | 0.0% |
| 2007 | - AUD | 0.0% |
| 2006 | - AUD | -100.0% |
| 2005 | 37.45 Thousand AUD | -72.91% |
| 2004 | 138.24 Thousand AUD | -39.8% |
| 2003 | 229.63 Thousand AUD | -33.82% |
| 2002 | 347 Thousand AUD | 57.73% |
| 2001 | 220 Thousand AUD | 511.11% |
| 2000 | 36 Thousand AUD | 0.0% |
| 1999 | - AUD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 993.07 Thousand AUD | 0.0% |
| 2024 FY | 2.33 Million AUD | 78.7% |
| 2024 Q4 | 23.59 Thousand AUD | 0.0% |
| 2023 Q4 | 1.3 Million AUD | 0.0% |
| 2023 Q2 | 1.2 Million AUD | 0.0% |
| 2023 FY | 1.3 Million AUD | 26.41% |
| 2022 FY | 1.03 Million AUD | -19.39% |
| 2022 Q4 | 1.03 Million AUD | 0.0% |
| 2022 Q2 | 1.16 Million AUD | 0.0% |
| 2021 Q2 | 7782.00 AUD | 0.0% |
| 2021 FY | 1.28 Million AUD | 850.47% |
| 2021 Q4 | 1.28 Million AUD | 0.0% |
| 2020 FY | 134.86 Thousand AUD | 0.0% |
| 2020 Q2 | 257.36 Thousand AUD | 0.0% |
| 2020 Q4 | 134.86 Thousand AUD | 0.0% |
| 2019 Q2 | - AUD | 0.0% |
| 2019 Q4 | - AUD | 0.0% |
| 2019 FY | - AUD | 0.0% |
| 2018 Q2 | - AUD | 0.0% |
| 2018 FY | - AUD | -100.0% |
| 2018 Q4 | - AUD | 0.0% |
| 2017 Q4 | 833.88 Thousand AUD | 0.0% |
| 2017 Q2 | - AUD | 0.0% |
| 2017 FY | 833.88 Thousand AUD | -88.8% |
| 2016 Q2 | - AUD | 0.0% |
| 2016 FY | 7.44 Million AUD | 0.0% |
| 2016 Q4 | 26.29 Million AUD | 0.0% |
| 2015 FY | - AUD | 0.0% |
| 2015 Q2 | - AUD | 0.0% |
| 2015 Q4 | - AUD | 0.0% |
| 2014 Q2 | - AUD | 0.0% |
| 2014 FY | - AUD | 0.0% |
| 2014 Q4 | - AUD | 0.0% |
| 2013 Q3 | - AUD | 0.0% |
| 2013 Q2 | - AUD | 0.0% |
| 2013 Q1 | - AUD | 0.0% |
| 2013 FY | - AUD | 0.0% |
| 2013 Q4 | - AUD | 0.0% |
| 2012 FY | - AUD | 0.0% |
| 2012 Q4 | - AUD | 0.0% |
| 2011 FY | - AUD | 0.0% |
| 2011 Q4 | - AUD | 0.0% |
| 2010 Q4 | - AUD | 0.0% |
| 2010 FY | - AUD | 0.0% |
| 2009 FY | - AUD | 0.0% |
| 2009 Q4 | - AUD | 0.0% |
| 2008 FY | - AUD | 0.0% |
| 2008 Q4 | - AUD | 0.0% |
| 2007 Q4 | - AUD | 0.0% |
| 2007 FY | - AUD | 0.0% |
| 2006 FY | - AUD | -100.0% |
| 2006 Q4 | - AUD | 0.0% |
| 2005 Q4 | 37.45 Thousand AUD | 0.0% |
| 2005 FY | 37.45 Thousand AUD | -72.91% |
| 2004 Q4 | 138.24 Thousand AUD | 0.0% |
| 2004 FY | 138.24 Thousand AUD | -39.8% |
| 2003 FY | 229.63 Thousand AUD | -33.82% |
| 2003 Q4 | 229.63 Thousand AUD | 0.0% |
| 2002 FY | 347 Thousand AUD | 57.73% |
| 2002 Q4 | 347.32 Thousand AUD | 0.0% |
| 2001 Q4 | 220.01 Thousand AUD | 0.0% |
| 2001 FY | 220 Thousand AUD | 511.11% |
| 2000 FY | 36 Thousand AUD | 0.0% |
| 1999 FY | - AUD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 123.85 Thousand AUD | 80.952% |
| Anatara Lifesciences Ltd | - AUD | -Infinity% |
| Zelira Therapeutics Limited | 5.65 Million AUD | 99.583% |
| Biome Australia Limited | 1.3 Million AUD | 98.193% |
| Patrys Limited | - AUD | -Infinity% |
| Orthocell Limited | 689.69 Thousand AUD | 96.579% |
| Imugene Limited | 1.54 Million AUD | 98.475% |
| Noxopharm Limited | - AUD | -Infinity% |
| PYC Therapeutics Limited | 1.11 Million AUD | 97.88% |
| Chimeric Therapeutics Limited | - AUD | -Infinity% |
| Prescient Therapeutics Limited | 330.48 Thousand AUD | 92.861% |
| Proteomics International Laboratories Limited | 316.39 Thousand AUD | 92.543% |
| Cynata Therapeutics Limited | - AUD | -Infinity% |
| CSL Limited | 18.24 Billion AUD | 100.0% |
| Arovella Therapeutics Limited | - AUD | -Infinity% |
| Bio-Gene Technology Limited | - AUD | -Infinity% |
| Clinuvel Pharmaceuticals Limited | 879.78 Thousand AUD | 97.318% |
| Starpharma Holdings Limited | 3.52 Million AUD | 99.331% |
| Nanollose Limited | 42.53 Thousand AUD | 44.529% |
| Memphasys Limited | 4.41 Million AUD | 99.465% |
| Invex Therapeutics Ltd | - AUD | -Infinity% |
| NeuroScientific Biopharmaceuticals Limited | - AUD | -Infinity% |
| Amplia Therapeutics Limited | 1.56 Million AUD | 98.489% |
| Botanix Pharmaceuticals Limited | - AUD | -Infinity% |
| Island Pharmaceuticals Limited | 421.96 Thousand AUD | 94.409% |
| Race Oncology Limited | - AUD | -Infinity% |
| Nyrada Inc. | - AUD | -Infinity% |
| Telix Pharmaceuticals Limited | 17.44 Million AUD | 99.865% |
| Dimerix Limited | 149.68 Thousand AUD | 84.239% |
| PharmAust Limited | - AUD | -Infinity% |
| Immutep Limited | 1.22 Million AUD | 98.079% |
| Clarity Pharmaceuticals Ltd | - AUD | -Infinity% |
| Alterity Therapeutics Limited | 159.04 Thousand AUD | 85.166% |
| BTC Health Limited | - AUD | -Infinity% |
| Acrux Limited | 1.48 Million AUD | 98.413% |
| Neuren Pharmaceuticals Limited | - AUD | -Infinity% |
| Biotron Limited | 7130.00 AUD | -230.884% |
| Tissue Repair Ltd | - AUD | -Infinity% |
| AdAlta Limited | 2.49 Million AUD | 99.054% |
| Radiopharm Theranostics Limited | - AUD | -Infinity% |
| Hexima Limited | - AUD | -Infinity% |
| Paradigm Biopharmaceuticals Limited | 239.33 Thousand AUD | 90.142% |
| Recce Pharmaceuticals Ltd | 811.19 Thousand AUD | 97.092% |
| Avecho Biotechnology Limited | 175.15 Thousand AUD | 86.53% |
| Actinogen Medical Limited | 319.06 Thousand AUD | 92.606% |
| Immuron Limited | 173.49 Thousand AUD | 86.402% |
| Argenica Therapeutics Limited | - AUD | -Infinity% |